Multiple resistance mechanisms, including secondary mutations, the activation of bypass signaling pathways, and tumor microenvironment adaptations, enable cancer cells to evade B-RAF inhibition and sustain oncogenic signaling [23,24]. Here, BRAF is linked to cancer.